{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:49:27Z","timestamp":1790948967046,"version":"4.1.0"},"reference-count":64,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Hypoparathyroidism is a rare endocrine disorder which leads to hypocalcemia, hypercalciuria, and hyperphosphatemia. Complications include nephrocalcinosis with renal dysfunction, reduced quality of life, and abnormal skeletal properties. Conventional therapy with calcium and vitamin D analogs addresses hypocalcemia but has important limitations. Parathyroid hormone (PTH) therapy is a fundamental advance, although the effects of PTH on long-term complications require additional testing. Continuous PTH therapy is likely to be particularly advantageous for addressing renal, quality of life, and skeletal complications. Overall, much progress has been made, yet more information is needed to improve our understanding and management of hypoparathyroidism.<\/ns4:p>","DOI":"10.12688\/f1000research.22717.1","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T09:35:45Z","timestamp":1595496945000},"page":"766","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Recent advances in understanding and managing hypoparathyroidism"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-2121","authenticated-orcid":false,"given":"Mishaela R.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"391-403","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice. Hypoparathyroidism.","volume":"359","author":"D Shoback","year":"2008","journal-title":"N Engl J Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"2317-37","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.","volume":"26","author":"J Bilezikian","year":"2011","journal-title":"J Bone Miner Res."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"2284-99","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and Diagnosis of Hypoparathyroidism.","volume":"101","author":"B Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"2570-6","DOI":"10.1002\/jbmr.2004","article-title":"Prevalence and Incidence of Hypoparathyroidism in the United States Using a Large Claims Database.","volume":"28","author":"J Powers","year":"2013","journal-title":"J Bone Miner Res."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1863-75","DOI":"10.1056\/NEJM200012213432508","article-title":"Hyperparathyroid and hypoparathyroid disorders.","volume":"343","author":"S Marx","year":"2000","journal-title":"N Engl J Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"19-22","DOI":"10.1097\/00125817-200101000-00005","article-title":"Endocrine aspects of the 22q11.2 deletion syndrome.","volume":"3","author":"S Weinzimer","year":"2001","journal-title":"Genet Med."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1443-52","DOI":"10.1016\/S0140-6736(07)61601-8","article-title":"Velocardiofacial syndrome, DiGeorge syndrome: The chromosome 22q11.2 deletion syndromes.","volume":"370","author":"L Kobrynski","year":"2007","journal-title":"Lancet."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"R127-42","DOI":"10.1530\/JME-16-0124","article-title":"Disorders of the calcium-sensing receptor and partner proteins: Insights into the molecular basis of calcium homeostasis.","volume":"57","author":"F Hannan","year":"2016","journal-title":"J Mol Endocrinol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"78-85","DOI":"10.1016\/j.autrev.2017.11.012","article-title":"The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1).","volume":"17","author":"C Guo","year":"2018","journal-title":"Autoimmun Rev."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"2273-83","DOI":"10.1210\/jc.2015-3907","article-title":"Management of Hypoparathyroidism: Summary Statement and Guidelines.","volume":"101","author":"M Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2300-12","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of Hypoparathyroidism: Etiologies and Clinical Features.","volume":"101","author":"D Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fendo.2016.00172","article-title":"Review of Hypoparathyroidism.","volume":"7","author":"E Abate","year":"2016","journal-title":"Front Endocrinol (Lausanne)."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2504-10","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections.","volume":"29","author":"L Underbjerg","year":"2014","journal-title":"J Bone Miner Res."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"2313-24","DOI":"10.1210\/jc.2015-3910","article-title":"Management of Hypoparathyroidism: Present and Future.","volume":"101","author":"J Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"4507-14","DOI":"10.1210\/jc.2012-1808","article-title":"Long-Term Follow-Up of Patients with Hypoparathyroidism.","volume":"97","author":"D Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2277-85","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study.","volume":"28","author":"L Underbjerg","year":"2013","journal-title":"J Bone Miner Res."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"3045-53","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway.","volume":"101","author":"M Astor","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"215-22","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D.","volume":"146","author":"W Arlt","year":"2002","journal-title":"Eur J Endocrinol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2748-2756","DOI":"10.1210\/jc.2018-02430","article-title":"Quality of Life in Hypoparathyroidism Improves with rhPTH(1-84) Throughout 8 Years of Therapy.","volume":"104","author":"G Tabacco","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1717-26","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: Results from a randomized controlled trial.","volume":"25","author":"T Sikjaer","year":"2014","journal-title":"Osteoporos Int."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"631-6","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism.","volume":"276","author":"K Winer","year":"1996","journal-title":"JAMA."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"3389-95","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism.","volume":"93","author":"K Winer","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"4214-20","DOI":"10.1210\/jc.2002-021736","article-title":"Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1\u201334) Versus Calcitriol and Calcium.","volume":"88","author":"K Winer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"2680-8","DOI":"10.1210\/jc.2009-2464","article-title":"Long-Term Treatment of 12 Children with Chronic Hypoparathyroidism: A Randomized Trial Comparing Synthetic Human Parathyroid Hormone 1\u201334 versus Calcitriol and Calcium.","volume":"95","author":"K Winer","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"3480-6","DOI":"10.1210\/jcem.83.10.5185","article-title":"A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1\u201334 in Treatment of Hypoparathyroidism.","volume":"83","author":"K Winer","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-26","article-title":"Natpara package insert 2015","year":"2015"},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"5601-10","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of Hypoparathyroidism With rhPTH(1\u201384): A Prospective, 8-Year Investigation of Efficacy and Safety.","volume":"104","author":"Y Tay","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"275-83","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): A double-blind, placebo-controlled, randomised, phase 3 study.","volume":"1","author":"M Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"2358-70","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study.","volume":"26","author":"T Sikjaer","year":"2011","journal-title":"J Bone Miner Res."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"5136-47","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.","volume":"104","author":"M Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"822-31","DOI":"10.1002\/jbmr.3368","article-title":"Long-Term Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study.","volume":"33","author":"L Underbjerg","year":"2018","journal-title":"J Bone Miner Res."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"dgz319","DOI":"10.1210\/clinem\/dgz319","article-title":"Nephrocalcinosis, Renal Dysfunction, and Calculi in Patients With Primary Hypoparathyroidism on Long-Term Conventional Therapy.","volume":"105","author":"S Saha","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"273-82","DOI":"10.1007\/s12020-016-1141-0","article-title":"Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.","volume":"55","author":"B Clarke","year":"2017","journal-title":"Endocrine."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1440-8","DOI":"10.1002\/jbmr.2812","article-title":"Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism.","volume":"31","author":"T Sikjaer","year":"2016","journal-title":"J Bone Miner Res."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1738-44","DOI":"10.1002\/jbmr.2501","article-title":"The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study.","volume":"30","author":"L Underbjerg","year":"2015","journal-title":"J Bone Miner Res."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"722-31","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.","volume":"103","author":"T Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"271-80","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.","volume":"103","author":"A Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1951-8","DOI":"10.1210\/jc.2008-2574","article-title":"Neuropsychological Features in Primary Hyperparathyroidism: A Prospective Study.","volume":"94","author":"M Walker","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"14-20","DOI":"10.1007\/s12020-017-1377-3","article-title":"Quality of life in patients with hypoparathyroidism receiving standard treatment: A systematic review.","volume":"58","author":"M B\u00fcttner","year":"2017","journal-title":"Endocrine."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"2232-43","DOI":"10.1002\/jbmr.1964","article-title":"PTH(1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.","volume":"28","author":"T Sikjaer","year":"2013","journal-title":"J Bone Miner Res."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"3694-9","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy.","volume":"99","author":"N Cusano","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"227-33","DOI":"10.1530\/acta.0.1060227","article-title":"Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid.","volume":"106","author":"S Balabanov","year":"1984","journal-title":"Acta Endocrinol (Copenh)."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"15455-8","DOI":"10.1074\/jbc.270.26.15455","article-title":"Identification and Functional Expression of a Receptor Selectively Recognizing Parathyroid Hormone, the PTH2 Receptor.","volume":"270","author":"T Usdin","year":"1995","journal-title":"J Biol Chem."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"51-8","DOI":"10.1016\/j.physbeh.2017.09.005","article-title":"The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice.","volume":"181","author":"B Gell\u00e9n","year":"2017","journal-title":"Physiol Behav."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"128-47","DOI":"10.1016\/j.neuroscience.2009.04.054","article-title":"Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human.","volume":"162","author":"A Bag\u00f3","year":"2009","journal-title":"Neuroscience."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"25-36","DOI":"10.2147\/PROM.S179310","article-title":"Psychometric evaluation of the hypoparathyroidism symptom diary.","volume":"10","author":"T Coles","year":"2019","journal-title":"Patient Relat Outcome Meas."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"2018-24","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism.","volume":"23","author":"M Rubin","year":"2008","journal-title":"J Bone Miner Res."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"190-5","DOI":"10.1016\/j.bone.2009.09.020","article-title":"Three dimensional cancellous bone structure in hypoparathyroidism.","volume":"46","author":"M Rubin","year":"2010","journal-title":"Bone."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"2727-36","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.","volume":"26","author":"M Rubin","year":"2011","journal-title":"J Bone Miner Res."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"251-8","DOI":"10.1210\/jc.2016-3292","article-title":"Vertebral Fractures and Bone Mineral Density in Patients With Idiopathic Hypoparathyroidism on Long-Term Follow-Up.","volume":"102","author":"H Chawla","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2742-50","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.","volume":"101","author":"M Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1931-9","DOI":"10.1002\/jbmr.3543","article-title":"The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry.","volume":"33","author":"M Rubin","year":"2018","journal-title":"J Bone Miner Res."},{"key":"ref-53","article-title":"Natpara package insert."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"556-563.e1","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of Pump versus Twice-Daily Injection Delivery of Synthetic Parathyroid Hormone 1-34 in Children with Severe Congenital Hypoparathyroidism.","volume":"165","author":"K Winer","year":"2014","journal-title":"J Pediatr."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"391-9","DOI":"10.1210\/jc.2011-1908","article-title":"Synthetic Human Parathyroid Hormone 1-34 Replacement Therapy: A Randomized Crossover Trial Comparing Pump Versus Injections in the Treatment of Chronic Hypoparathyroidism.","volume":"97","author":"K Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"ref-56","article-title":"Information on the recall of NATPARA in the US","year":"2020"},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"2112-8","DOI":"10.1002\/jbmr.2555","article-title":"Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.","volume":"30","author":"R Gafni","year":"2015","journal-title":"J Bone Miner Res."},{"key":"ref-58","article-title":"Endocrine Society Guidance On Transitioning Hypoparathyroidism Patients from NATPARA\u00ae","year":"2019"},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"2075-86","DOI":"10.1002\/jbmr.3824","article-title":"Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.","volume":"34","author":"L Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res."},{"key":"ref-60","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.56.GP174","article-title":"The design and preliminary results of a phase 1 TransCon PTH trial in healthy volunteers.","author":"D Karpf","year":"2018","journal-title":"EJEA."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.1038\/ncomms13384","article-title":"Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.","volume":"7","author":"T Tamura","year":"2016","journal-title":"Nat Commun."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1405-12","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.","volume":"31","author":"M Shimizu","year":"2016","journal-title":"J Bone Miner Res."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"975-84","DOI":"10.1002\/jbmr.2769","article-title":"Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog.","volume":"31","author":"R Bi","year":"2016","journal-title":"J Bone Miner Res."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"931-43","DOI":"10.1210\/me.2005-0349","article-title":"Mechanisms of ligand binding to the parathyroid hormone (PTH)\/PTH-related protein receptor: Selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations.","volume":"20","author":"T Dean","year":"2006","journal-title":"Mol Endocrinol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-766\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-766\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-766\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T09:45:17Z","timestamp":1595497517000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-766\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":64,"URL":"https:\/\/doi.org\/10.12688\/f1000research.22717.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.25084.r67011","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.25084.r67012","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-766\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.25084.r67011, Bart Clarke, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, MN, USA, 23 Jul 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-766\/v1#referee-response-67011","order":0,"name":"referee-response-67011","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.25084.r67012, Maria Luisa Brandi, Department of Surgery and Translational Medicine, Bone Metabolic Diseases Unit, University of Florence, Florence, Italy, 23 Jul 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-766\/v1#referee-response-67012","order":1,"name":"referee-response-67012","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}